Objective:To investigate the effects of semaglutide combined with empagliflozin on blood uric acid,oxidative stress,and glucolipid metabolism in patients with perimenopausal diabetes mellitus with metabolic syndrome.Methods:A total of 196 patients with perimenopausal diabetes mellitus with metabolic syndrome were selected as the study subjects and divided into groups according to the treatment measures adopted,among which the control group(n=98)was treated with metformin empagliflozin,and the observation group(n=98)was treated with semaglutide on the basis of the control group,with a treat-ment course of 6 months for both groups.Efficacy,blood glucose[fasting blood glucose(FPG),2-hour postprandial blood glu-cose(2hPG),and glycated hemoglobin(HbA1c)levels],blood lipids[total cholesterol(TC),low-density lipoprotein cholester-ol(LDL-C),and high-density lipoprotein cholesterol(HDL-C)levels],blood uric acid,islet function[insulin resistance index(Homa-IR)],oxidative stress[lipid hydroperoxide(LHP)and superoxide dismutase(SOD)levels]and inflammation[inter-leukin-6(IL-6)and tumor necrosis factor alpha(TNF-α)]were recorded and compared between the two groups.Results:The effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of FPG,2hPG,HbA1c,TC,LDL-C,serum uric acid,HOMA-IR,LHP,IL-6,and TNF-α in the observation group were lower than those in the control group,while the levels of(HDL-C and SOD were higher than those in the control group(P<0.05).Conclusion:The efficacy of semaglutide combined with metformin and empagliflozin in the treatment of perimenopausal diabetes mellitus with metabolic syndrome is better,which is able to reduce the patient's blood uric acid level,optimize glucose and lipid metabolism,and improve the inflammation and stress state of the body,which is worthy of being promoted for use in the clinic.